23 results about "Spleen Tissue" patented technology

The application discloses a use of Ejiao Qianggu oral liquid in regulating immunity, and particularly relates to an improving effect of the Ejiao Qianggu oral liquid on an immune system, which is realized by the following aspects. On one hand, the Ejiao Qianggu oral liquid promotes proliferation and transformation (mainly early T lymphocytes and part of B lymphocytes) and active functions of spleen lymphocytes; on the other hand, the Ejiao Qianggu oral liquid improves phagocytosis of macrophages. The Ejiao Qianggu oral liquid has the following characteristics: firstly, the Ejiao Qianggu oral liquid acts on early lymphocyte maturation, and has no significant effect on proliferation of peripheral blood lymphocytes; secondly, the Ejiao Qianggu oral liquid can significantly act on immune target organs, thymus and spleen tissues, and does not excessively stimulate the spleen, unlike positive drugs such as colony stimulating factor which can cause significant edema of the spleen; and thirdly, the Ejiao Qianggu oral liquid has a significant recovery effect on body weight, white blood cells, lymphocytes, red blood cells and hemoglobin in blood of patients with low immunity.

The present invention provides lipid nanoparticles for delivering nucleic acid to spleen tissue that can improve the efficiency of nucleic acid delivery to spleen tissue cells, and a method for delivering nucleic acid to spleen tissue by using same. A lipid nanoparticle for use in delivering a nucleic acid to a spleen tissue, including(A) an ionic lipid represented by the formula (1),(B) an anionic phospholipid or a compound represented by the formula (2),(C) cholesterol, and(D) a dimyristoylglycerol PEG represented by the formula:(definitions of symbols in the formula are as described in the specification), and a method for delivering a nucleic acid to a spleen tissue by using same.

The present application provides a kind of bioactive seventeen peptides and its application, belong to bioactive peptide technical field, the amino acid sequence of the seventeen peptides is as shown in SEQ ID NO.1;Seventeen peptides provided by the present application can significantly reduce immune damage, improve immune organ index, reduce spleen tissue damage, can significantly promote the secretion level of immunoglobulin and cytokine in blood;The polypeptide has immunoregulation, can improve immunity, can be used for preparing the product of enhancing immunity.

The present application provides a kind of PRMT5 inhibitor, PRMT5 inhibitor includes: recombinant adeno-associated virus vector AAV-shPrmt5 and GSK3326595;Recombinant adeno-associated virus vector AAV-shPrmt5 includes the shRNA of targeting PRMT5, the nucleotide sequence of shRNA is as shown in SEQ ID No:1.The present application also provides the application of the above-mentioned PRMT5 inhibitor in the preparation of drug for improving primary biliary cholangitis, PRMT5 inhibitor is all PRMT5 gene / protein as target point, by inhibiting the expression of PRMT5 gene / protein, reduce liver tissue and spleen tissue Tfh cell and GC B cell, serum autoantibody and transaminase level, can effectively delay the disease progression of primary biliary cholangitis.

The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for preventing and treating leucopenia as well as a preparation method and application thereof. The composition is prepared from fructus momordicae, fructus ligustri lucidi, ginseng leaves and roses as raw materials through extraction. Experiments show that the composition can significantly increase the number and vitality of leukocytes so as to play multiple roles in increasing leukocytes, improving pathological injury of spleen tissues and enhancing immunity, and the effects are significantly superior to those of a formula-lacking control or a formula-replacing control. Therefore, all the components in the composition cooperate with one another and take effect synergistically, and are indispensable.

This invention belongs to the field of animal feed technology and discloses the application of glucuronolactone in the preparation of feed that alleviates spleen damage caused by the combined effects of PRRSV and DON. This invention discovers that glucuronolactone can effectively alleviate spleen damage in piglets caused by co-exposure to PRRSV and DON. It exerts its protective effect by activating the Nrf2 antioxidant signaling pathway, improving spleen tissue structure, alleviating oxidative stress, inhibiting inflammatory responses, and inhibiting apoptosis. This invention also provides a feed containing the aforementioned effective amount of glucuronolactone, with the basic feed tailored to the nutritional needs of piglets. This invention fills the technological gap in effective intervention methods for spleen damage under PRRSV and DON co-exposure. The glucuronolactone addition process is simple, the effect is significant, and it is suitable for large-scale feed production. It can effectively solve the problem of immunosuppression in pig herds caused by the combined harm of PRRSV and DON in the pig industry, and has important practical value.

The invention provides application of low-intensity focused ultrasound in preparation of a noninvasive asthma treatment product, and belongs to the technical field of asthma treatment. The low-intensity focused ultrasound treats the asthma by regulating and controlling the activity of the spleen nerves, the low-intensity focused ultrasound has high targeting, accuracy and durability on the asthma, and the spleen histological injury or dysfunction of adjacent organs (such as pancreas and kidneys) is not observed, so that the effectiveness and safety of the technology are proved.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition, a preparation method and application thereof. Specifically, based on the theory of traditional Chinese veterinary medicine of'strengthening the body resistance and eliminating pathogenic factors, and treating the root and branch', aiming at the pathogenesis of 'deficiency in the root and excess in the branch' of low immunity in animals, eight kinds of medicinal materials are scientifically screened to form a traditional Chinese medicine compound with the effects of tonifying qi and nourishing blood, invigorating the spleen and kidney, dredging collaterals and eliminating dampness, and clearing heat and detoxifying. Through the verification of a cyclophosphamide-induced low immunity mouse model, the traditional Chinese medicine composition can significantly improve the mental state of the mice, restore the body weight and thymus / spleen index, repair the pathological damage of the spleen tissue, and adjust the inflammatory factor level in the serum and spleen tissue. In addition, in a Marek's disease virus infection model, the traditional Chinese medicine composition combined with the Marek's disease virus vaccine can significantly reduce the viral load in the peripheral blood, liver and spleen, and reduce the liver enlargement, hemorrhage and microscopic structure damage, showing a good immune synergistic effect.

The invention relates to the technical field of polypeptide preparation, and discloses a spleen extract preparation method, which comprises: carrying out pretreatment, homogenization, freeze thawing crushing, precipitation separation and ultrafiltration on a mammal spleen tissue to obtain a spleen polypeptide extract; coupling the spleen polypeptide extract with ADC through a chemical coupling bridge to form a targeting compound; preparing an antioxidant-basic amino acid compound; mixing the coupling compound with a wall material solution containing a functional filling agent and an antioxidant-alkaline amino acid compound, and carrying out microencapsulation embedding; carrying out freeze drying on the microcapsules; and spraying a chitosan-sodium carboxymethyl cellulose polyelectrolyte compound on the surface of the freeze-dried microcapsule to carry out hydrophilic modification. The antioxidant-basic amino acid compound is used for blocking intermolecular chemical crosslinking, the cyclodextrin inclusion effect is used for preventing aggregation, and the polysaccharide composite hydrophilic layer is used for providing environmental tolerance, so that the chemical crosslinking rate of the product is reduced by 80% or above, and the aggregation rate is reduced to 5% or below.

The invention discloses application of a xanthoceras sorbifolia extract in preparation of a medicine for preventing and / or treating electromagnetic radiation damage. Experiments show that the xanthoceras sorbifolia bunge flower extract can improve the weight loss of rats caused by microwave radiation; brain tissue structure change damage caused by microwave radiation is improved; the reduction of the learning and memory ability of the rats caused by microwave radiation is improved; the brain sea horse tissue amino acid neurotransmitter disorder caused by microwave radiation is improved; electroencephalogram alpha and beta wave abnormity caused by microwave radiation is improved; the sperm motility reduction caused by microwave radiation is improved; the rat serum sex hormone disorder caused by microwave radiation is improved; rat testicular tissue oxidative stress injury caused by microwave radiation is improved; the abnormal energy metabolism of testicular tissues caused by microwave radiation is improved; heart electrophysiological abnormality and heart tissue ultrastructure abnormality caused by microwave radiation are improved; the immune function decline caused by microwave radiation is improved; the influence of microwave radiation on the content of IL-2, 4 is improved; the influence of microwave radiation on the thymus and spleen tissue structure is improved.

The invention provides a novel application of a macleaya cordata extract as a salmonella type III secretion system (T3SS) inhibitor. Through construction of a chick infection model and in-vitro experiments, the extract is proved to be capable of remarkably reducing the bacterial load of infected chick liver and spleen tissues, relieving tissue pathological damage and reducing inflammatory cell infiltration. Mechanism research shows that the macleaya cordata extract can down-regulate the expression of T3SS key virulence protein SipA in a dose-dependent manner, interfere the function of a secretion system, and further block the secretion and expression of virulence factors. The invention discloses the potential application of the macleaya cordata extract in the aspect of resisting salmonella toxicity for the first time, and provides a development strategy and a technical basis of a T3SS inhibitor from a natural product.

Embodiments of the present application provide a spleen structure analysis method and device, electronic equipment and storage medium. The method comprises obtaining a spleen structure analysis request, the spleen structure analysis request comprising first single-cell sequencing data and first spatial transcriptome sequencing data of a spleen tissue to be analyzed; determining a plurality of first significantly expressed gene data corresponding to a plurality of cell types according to the first single-cell sequencing data, and determining a plurality of second significantly expressed gene data corresponding to a plurality of spleen partitions according to the first spatial transcriptome sequencing data; determining a first intersection between the second significantly expressed gene data of each spleen partition and the first significantly expressed gene data of each cell type, and constructing an input data set based on the first intersection; determining a spleen structure analysis result according to the similarity between the input data set and a reference data set, the reference data set being a data set corresponding to a spleen sample of a reference spleen structure. The method can improve the accuracy of spleen structure analysis.

This invention relates to the field of biomedical technology, and discloses a 6mA modified single-stranded DNA sequence that specifically binds to the MYH9 protein and its application in the treatment of sepsis; the single-stranded DNA sequence is specifically bound to the MYH9 protein. N 6 A single-stranded DNA sequence modified with 6mA-methyladenine (nucleotide sequence shown in SEQ ID NO:1) exhibits a specific adenine (A) methylation at a specific position, which allows it to be specifically recognized and bound by the MYH9 protein. The binding specificity was verified in vitro / in vivo using EMSA, biotin DNA pulldown WB assays, and MYH9-DNA IP assays. This 6mA-modified single-stranded DNA, by binding to the MYH9 protein, activates the downstream JAK1-STAT6 signaling pathway, promoting macrophage polarization towards the M2 phenotype, inhibiting excessive inflammatory responses, improving survival rates, reducing pathological damage to spleen tissue, and ameliorhythmic symptoms such as weight loss and hypothermia in septic mice, thereby exerting an anti-septic effect. This effectively addresses the clinical pain points of existing non-specific anti-inflammatory therapies and possesses significant potential for drug development.

The present invention relates to a novel Pediococcus acidilactici WiKim0170 strain having immunity-enhancing efficacy and a composition for enhancing immunity, comprising same. In the present invention, it has been discovered that the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, significantly increases spleen NK cell activity and increases inflammatory mediator, immunoglobulin, and cytokine production amounts, thereby improving an immunosuppressive reaction. In addition, the Pediococcus acidilactici WiKim0170 strain has been confirmed to increase the mRNA expression levels of iNOS, COX2, TNF-α, IL-1β, IL-6, IL-2, IL-12, and IL-10 in spleen tissue and increase the phosphorylation levels of NF-κB and IκBα, thereby having an effect of mitigating decreased immunity. Thus, according to the present invention, the composition comprising the Pediococcus acidilactici WiKim0170 strain, which is a novel strain derived from makgeolli, as an active ingredient is expected to be usefully employable as a pharmaceutical and functional food composition for enhancing immunity.

The invention discloses application of an NASH-HCC mouse model, and belongs to the technical field of drug evaluation. The NASH-HCC mouse model can be applied to screening and / or evaluation of drugs and / or equipment for treating and / or preventing liver diseases, the NASH-HCC mouse model is an inducible Cre mouse, the HRAS protein is specifically and highly expressed in the liver under the induction of an inducer, and the liver diseases are NAFLD, NASH or HCC. The model can comprehensively evaluate the curative effect of a drug treatment scheme through multiple aspects such as mouse liver weight, blood biochemical indexes, total ROS (reactive oxygen species) amount of liver and spleen tissues, immune cell change conditions and the like, and provides support and assistance for clinical application.

The invention discloses an application of Harman alkali in the aspect of preparing a Pseudomonas plecoglossicida inhibitor, and is characterized in that the Harman alkali is applied in the aspect of preparing a medicine for preventing and / or treating aquatic animal infectious diseases caused by Pseudomonas plecoglossicida. The invention further provides application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating aquatic animal plecoglossus altivelis pseudomonas infection, application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and treating plecoglossus altivelis liver injury, application of a plecoglossus altivelis immunoregulation medicine and application of the harman alkali or the pharmaceutically acceptable salt thereof in preparation of an aquaculture feed additive. The method has the advantages that the survival rate of aquatic animals can be remarkably increased in a Pseudomonas plecoglossicida infection model, the bacterial load in immune tissues such as blood, liver, spleen, head and kidney and the like is reduced, and liver and spleen tissue pathological injury and cell apoptosis caused by infection are relieved; meanwhile, harmine can improve biochemical and antioxidant indexes of infection-related serum, and has no obvious toxicity to fish-derived cells within a certain concentration range.

The invention provides an antibody-exosome, a preparation method thereof and application of the antibody-exosome in preparation of ricin detoxification drugs, and belongs to the technical field of drug delivery and intracellular therapy. The antibody-exosome disclosed by the invention comprises a milk-derived exosome (mExo) and a single-domain antibody V9E1 of an anti-ricin A chain; the amino acid sequence of the V9E1 is as shown in SEQ ID NO. 1. V9E1 is loaded into a milk exosome by using a saponin perforation method to obtain a V9E1 antibody-exosome, and the antibody-exosome shows reliable biological safety in both cells and animal bodies; the cell survival rate can be obviously improved in a Vero cell acute poisoning model; after mice are poisoned by ricin for 2 hours and 6 hours, the survival rate of the mice can be remarkably improved; through continuous administration, all mice injected with ricin with a complete lethal dose can survive, liver and spleen tissues can be protected, and the method has the potential of replacing a traditional ricin antibody therapy.

The application belongs to the technical field of biological genetic engineering, and relates to application of PRMT7 as a target point in preparation of a medicine for inhibiting proliferation of subgroup J avian leukemia virus, and application of a PRMT7 gene polymorphism site as a molecular marker for evaluating resistance of poultry to subgroup J avian leukemia virus. Research shows that PRMT7 is involved in immune regulation of a host to infection of subgroup J avian leukemia virus, and inhibition of PRMT7 expression can enhance activity of a type I interferon related path and reduce a virus replication level. Further, a plurality of nucleotide polymorphism sites in the PRMT7 gene are screened to obtain a significant correlation with an ALV-J related phenotype, and the related phenotype includes a pancreas tissue index, a spleen tissue index, a bursa of fabricius tissue index, an IL-6 level and an IFN alpha level. The application provides a new technical scheme for prevention and control of subgroup J avian leukemia virus, development of an antiviral target point and poultry disease resistance molecular breeding.

This invention provides a lipid compound and its applications, the results of which are shown in Formula I. The lipid compound provided by this invention can be used for targeted delivery of bioactive molecules to splenic T cells, particularly suitable for transporting negatively charged nucleic acid molecules, such as mRNA, providing a potential delivery strategy for in vivo specific gene editing of T cells. This invention also provides a bioactive substance delivery system comprising the lipid compound, which is loaded with bioactive substances. The bioactive substance delivery system of this invention, after intravenous administration, can efficiently target spleen tissue and selectively deliver active substances to T cells within the spleen, achieving efficient T cell transfection and immune activation. The delivery system of this invention has a simple synthesis process and strong structural tunability, and has broad application prospects in the fields of T cell immunotherapy and gene therapy.

Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and / or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue / cell).

The application relates to the technical field of biological extraction, and discloses a spleen polypeptide extract as well as a preparation method and application thereof. The preparation method takes fresh spleen tissue as raw material, and realizes preliminary separation of proteins, polypeptides and nucleic acids through an optimized isoelectric point grading process after pretreatment, homogenization, repeated freeze-thaw crushing, centrifugal separation and ultrafiltration grading, and finally obtains high-content products by adopting targeted chromatography purification technology. The spleen polypeptide extract and related products can be widely applied to the fields of biological medicines (such as immunomodulators and blood substitutes), food additives (such as protein fortifiers) and scientific reagent fields, the process is mild and has good repeatability, the comprehensive utilization of the spleen raw material is realized, the product added value is improved, and the application prospect of industrialization is good.

Provided herein are, inter alia, compositions and methods useful for the in vivo delivery of bioactive agents (e.g., therapeutic or diagnostic agents). The compositions provided herein include cationic lipids, helper lipids and a biostability enhancing agent, which together form a lipid aggregate with the bioactive agent and allow for the systemic delivery of the bioactive agent to, for example, spleen tissue without the requirement for biomolecular targeting.

The invention discloses a spleen neutrophil detection kit and a detection method thereof, and relates to the technical field of biological detection.The spleen neutrophil detection kit specifically comprises a sample treatment reagent, a cell separation reagent, a detection recognition reagent, a dyeing auxiliary reagent and a detection auxiliary reagent, collagen is specifically decomposed and free DNA is degraded through enzyme digestion, cell aggregation is prevented, and the detection accuracy is improved. In this way, efficient dissociation of spleen tissue is achieved, cell damage is reduced while a single-cell suspension is obtained, selective hypotonic lysis of red blood cells is achieved through a red blood cell lysis solution, white blood cells and neutrophils are reserved, the red blood cells are classified, the phenomenon that the red blood cells interfere with subsequent detection is avoided, and the detection accuracy is improved. Meanwhile, the density difference between the neutrophile granulocytes and other leukocytes is utilized, rapid separation is achieved in a centrifugal layering mode, the neutrophile granulocytes can be concentrated on an interface layer, separation, quantification and identification of the spleen neutrophile granulocytes are achieved, the initial enrichment efficiency is improved, and the reliability of subsequent detection results is ensured.